National Comprehensive Cancer Network



About NCCN

Neuroendocrine Tumors Panel - Disclosures as of 9/28/2011

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Al B. Benson III, MD, FACP

None

Abbott Laboratories;
Amgen Inc.;
AstraZeneca Pharmaceuticals LP;
Bayer HealthCare;
Eli Lilly and Company;
General Electric;
Genomic Health, Inc.;
National Cancer Institute;
Onyx Pharmaceuticals, Inc.

None

None

8/31/2012

Emily Bergsland, MD

Genentech, Inc.;
Novartis Pharmaceuticals Corporation;
sanofi-aventis U.S.

Novartis Pharmaceuticals Corporation

None

None

10/14/2012

Jordan D. Berlin, MD

Abbott Laboratories;
Amgen Inc.;
Bayer HealthCare;
Genentech, Inc.;
ImClone Systems Incorporated;
Pfizer

Amgen Inc.;
AstraZeneca Pharmaceuticals LP;
Enzon Pharmaceuticals;
Novartis Pharmaceuticals Corporation;
Roche Laboratories, Inc.

None

None

12/9/2012

Lawrence S. Blaszkowsky, MD

Genentech, Inc.;
GlaxoSmithKline

None

None

None

9/28/2011

Michael A. Choti, MD, MBA

None

Bristol-Myers Squibb Company;
Genentech, Inc.;
sanofi-aventis U.S.

None

None

2/12/2013

Orlo H. Clark, MD

Xoma

Xoma

What Company?

None

3/8/2013

Gerard M. Doherty, MD

None

Novartis Pharmaceuticals Corporation

None

None

6/2/2011

Mary Dwyer, MS

None

None

None

None

3/26/2013

James Eason, MD

None

None

None

None

1/30/2012

Lyska Emerson, MD

None

None

None

None

8/9/2012

Paul F. Engstrom, MD, FACP

None

None

None

None

2/27/2013

Deborah Freedman-Cass, PhD

None

None

None

None

3/7/2013

Lauren Gallagher, RPh, PhD

None

None

None

None

6/5/2012

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

10/23/2012

Martin J. Heslin, MD

None

None

None

None

10/8/2012

Fouad Kandeel, MD, PhD

None

Molecular Insights Pharmaceuticals

None

None

8/17/2012

Anne Kessinger, MD

Pharmacyclics;
sanofi-aventis U.S.

None

None

None

5/4/2011

Matthew H. Kulke, MD

None

Novartis Pharmaceuticals Corporation;
Ipsen;
Lexicon;
Pfizer Inc.

None

None

8/9/2012

Pamela L. Kunz, MD

None

None

None

None

9/3/2012

Boris W. Kuvshinoff, MD, MBA

None

None

None

None

10/24/2012

Joan S. McClure, MS

None

None

None

None

7/23/2012

Jeffrey F. Moley, MD

None

None

None

None

10/8/2012

John A. Olson, MD, PhD

None

None

None

None

12/3/2009

Venu G. Pillarisetty, MD

None

None

None

None

8/16/2012

Leonard Saltz, MD

None

Abbott Laboratories;
CureTech Ltd.;
Genentech, Inc.;
Genomic Health, Inc.;
Genzyme Corporation;
Merck & Co., Inc.;
Novartis Pharmaceuticals Corporation;
Asuragen, Inc.;
Roche Laboratories, Inc.;
YM BioScience Inc.

None

None

8/27/2012

David E. Schteingart, MD

None

None

None

None

4/9/2012

Manisha H. Shah, MD

None

Novartis Pharmaceuticals Corporation

None

None

8/20/2012

Stephen Shibata, MD

None

Genentech, Inc.;
Genomic Health, Inc.

None

None

6/22/2011

Jonathan R. Strosberg, MD

Pfizer Inc.

Endo Pharmaceuticals

None

None

11/9/2012

Jean-Nicolas Vauthey, MD

None

None

None

None

9/13/2012

James C. Yao, MD

None

National Cancer Institute;
Novartis Pharmaceuticals Corporation;
Pfizer Inc.

None

None

11/28/2012

 

About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved